CAG方案治疗35例老年初治急性髓性细胞白血病的疗效观察

Clinical Efficacy of CAG Regimen Used in 35 Cases of Newly Diagnosed Acute Myeloid Leukemia in Elderly Patients

目的:观察CAG方案治疗老年初治急性髓性细胞白血病的临床疗效。方法:35例老年急性髓性细胞白血病患者随机分为两组,对照组患者(15例)采用标准化疗方案治疗;CAG组患者(20例)采用CAG方案(阿糖胞苷、阿克拉霉素、粒细胞集落刺激因子)治疗。治疗一个疗程后观察患者化疗疗效,比较两组患者中性粒细胞和血小板恢复时间以及药品不良反应发生率。结果:CAG组患者的治疗有效率为90%,明显高于对照组患者的60%(P<0.05)。CAG组患者的中性粒细胞和血小板恢复时间均明显短于对照组患者(P<0.05)。CAG组不良反应总发生率明显低于对照组(P<0.05)。结论:CAG方案治疗35例老年初治急性髓性细胞白血病化疗效果良好,可有效控制病情发展,加速血细胞恢复,安全性高。

Objective： To study the efficacy of CAG regimen used in 35 cases of newly diagnosed acute myeloid leukemia in elderly patients. Methods： Totally 35 cases of elderly patients with acute myeloid leukemia were randomly divided into two groups. The patients in the control group （15 cases） were treated with standard chemotherapy treatment, while the CAG regimen group （20 cases） was treated with CAG regimen （cytarabine, aclarubicin and granulocyte colony-stimulating factor）. After one treatment course, the chemotherapy efficacy was observed, and the neutrophil and platelet recovery time and the incidence of adverse reactions in the two groups were compared. Results： The treatment efficacy of the CAG regimen group was 90%, which was higher than that of the control group （60%, P 〈 0.05 ）. The neutrophil and platelet recovery time of the CAG regimen group was significantly shorter than that of the control group （P 〈 0.05 ）. The incidence of adverse reactions in CAG regimen group was much lower than that of the control group（ P 〈 0.05）. Conclusion： The efficacy of CAG regimen used in the 35 cases of newly diagnosed acute myeloid leukemia in elderly pa- tients is promising, which can effectively control the progression of the disease and accelerate blood cell recovery with high safety.